Form 4: Recursion Pharmaceuticals Director Acquires Shares Through Compensation Policy

Director Dean Y. Li acquired 1,647 shares of Class A Common Stock in Recursion Pharmaceuticals through the company's Outside Director Compensation Policy.

Summary

• Dean Y. Li, a director at Recursion Pharmaceuticals, acquired 1,647 shares of Class A Common Stock on January 2, 2025.
• The shares were acquired as part of the company's Outside Director Compensation Policy.
• The acquisition was a direct transaction, and the price per share was $0.
• Following the transaction, Mr. Li directly owns 77,350 shares of Class A Common Stock.
• Mr. Li also indirectly owns 1,422,048 shares through the Dean Li and Ruth Li Revocable Trust, 1,269,796 shares through the Dean Y. Li GRAT, and 421,000 shares through the Dean Y. Li 2021 Family Trust.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• The use of the Outside Director Compensation Policy indicates a structured approach to director compensation.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Director compensation through stock grants is a common practice in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• Many companies use similar compensation policies to align the interests of directors with those of shareholders.
• The number of shares acquired is relatively small compared to the total shares owned by the director, which is not unusual for routine compensation grants.

Stakeholder Impact

• The share acquisition has a minor positive impact on shareholders as it aligns director interests with the company's performance.

Key Dates

Keywords

Recursion Pharmaceuticals, Director, Share Acquisition, Compensation Policy, Class A Common Stock, Dean Y. Li, Insider Trading